UK – UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets. This includes the company’s lead pre-clinical ADC candidate IKS03, a potentially ‘best-in-class’ CD19-targeted asset for B-cell cancers. Iksuda will use the funds to support the progression of IKS03 into first-in-human Phase clinical trials, and will also be used to fast-track its earlier-stage programs. Currently, the company’s drug development pipeline is focused on the improved safety and efficacy…
Read MoreBiosphere tenant Iksuda Therapeutics raises $47m to reinforce Antibody Drug Conjugate pipeline
